SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike stock is facing significant volatility and trending downward after investors reacted negatively to conservative guidance and ongoing concerns about soft sales in China, despite the company posting a double earnings beat. The community is deeply divided, with many retail investors labeling the brand as 'stale' or 'woke' while others view the depressed price as a generational buying opportunity for a long-term turnaround.

Tema ETF Trust - Tema Space Innovators ETF

The newly launched Tema Space Innovators ETF (NASA) is drawing significant attention as traders debate whether its small asset base and exposure to SpaceX represent a promising new momentum play or a potential risk. Community discussion is sharply divided, with some investors eyeing the ticker for its high-volatility potential and similarities to recent thematic ETF surges, while others express skepticism over its low assets under management and limited holdings.

Ganymede

Ganymede is drawing attention as market participants highlight its clean structural formation and consistent buyer interest, fueling community optimism about its potential for growth. Traders are actively discussing the token's quiet momentum and controlled price action, viewing current levels as a favorable accumulation phase.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound (COMP) is seeing intense community debate as investors weigh its status as a battle-tested DeFi protocol against significant price volatility and concerns over governance efficacy. While some holders point to a capped supply and potential for V4 protocol updates as a catalyst for a rebound, many participants are expressing frustration over persistent downward pressure and are actively comparing its performance to competitors like AAVE.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently a focal point for community discussion as investors debate its long-term potential amid significant leadership changes and a shift toward U.S.-based institutional operations. While some users express frustration over stagnant price action and recent market lows, a vocal segment of the community remains focused on the project's real-world utility, recent regulatory clarity, and its ongoing efforts to scale institutional adoption.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors digest the commercial launch of Yartemlea following recent FDA approval and look ahead to upcoming earnings for initial revenue insights. Community discussion remains focused on the company's strong cash position, the strategic potential of the Novo Nordisk partnership, and anticipation of a potential squeeze as market participants weigh long-term value against ongoing short interest.

Maul Coin

Maul Coin is currently trending as the community rallies to drive organic growth through coordinated promotion and social media engagement, aiming to push the project to higher market cap milestones. Investors are actively discussing the importance of holding, community-led burning mechanisms, and the push for official chart integration to establish long-term legitimacy.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending as investors weigh recent strategic growth initiatives, including new commercialization partnerships in the metabolic and obesity drug space, against broader concerns regarding patent cliffs and shifting demand in its core vaccine segment. The community is actively discussing the stock's long-term potential as a dividend-paying value play while closely monitoring its oncology pipeline and speculative M&A sentiment within the biotech sector.

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Dexcom Inc

Dexcom is currently at the center of intense debate among retail traders who are vocally frustrated by stagnant price action and perceived market manipulation, while technical analysts closely monitor critical support levels and potential gap-fill opportunities following the company's recent product developments. The community is actively debating whether the stock is an oversold buying opportunity poised for a technical bounce or a fundamental value trap facing continued institutional selling pressure.

Applied Digital Corporation

Applied Digital is experiencing extreme volatility as investors weigh the company's long-term AI infrastructure potential against a broader market sell-off triggered by geopolitical uncertainty. The community is actively debating whether to treat the current pullback as a deep-value buying opportunity ahead of upcoming earnings or to prepare for further downside amid concerns regarding market-wide risk-off sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HC Wainwright Lowers Earnings Estimates for Jade Biosciences

Jade Biosciences, Inc. (NASDAQ:JBIO - Free Report) - Research analysts at HC Wainwright cut their Q1 2026 EPS estimates for Jade Biosciences in a note issued to investors on Wednesday, March 25th. HC...

Jade Biosciences (NASDAQ:JBIO) Price Target Raised to $35.00 at HC Wainwright

HC Wainwright increased their target price on shares of Jade Biosciences from $25.00 to $35.00 and gave the company a "buy" rating in a research report on Wednesday...

Jade Biosciences (NASDAQ:JBIO) Shares Gap Up After Analyst Upgrade

Jade Biosciences (NASDAQ:JBIO) Shares Gap Up Following Analyst Upgrade...

Jade Biosciences (NASDAQ:JBIO) Price Target Raised to $39.00 at BTIG Research

BTIG Research boosted their target price on Jade Biosciences from $28.00 to $39.00 and gave the stock a "buy" rating in a research note on Monday...

Zacks Research Downgrades Jade Biosciences (NASDAQ:JBIO) to Strong Sell

Zacks Research lowered Jade Biosciences from a "hold" rating to a "strong sell" rating in a research note on Tuesday...

Guggenheim Forecasts Strong Price Appreciation for Jade Biosciences (NASDAQ:JBIO) Stock

Guggenheim lifted their price target on shares of Jade Biosciences from $17.00 to $23.00 and gave the company a "buy" rating in a research note on Wednesday...

Jade Biosciences (NASDAQ:JBIO) Sees Unusually-High Trading Volume Following Analyst Upgrade

Jade Biosciences (NASDAQ:JBIO) Sees Strong Trading Volume on Analyst Upgrade...

Wedbush Reaffirms Outperform Rating for Jade Biosciences (NASDAQ:JBIO)

Wedbush reissued an "outperform" rating and issued a $24.00 price target on shares of Jade Biosciences in a research report on Monday...

Jade Biosciences, Inc. (NASDAQ:JBIO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Jade Biosciences, Inc. (NASDAQ:JBIO - Get Free Report) has received an average rating of "Moderate Buy" from the seven ratings firms that are presently covering the firm, MarketBeat.com reports. One...

Jade Biosciences (NASDAQ:JBIO) Upgraded by Lifesci Capital to "Strong-Buy" Rating

Lifesci Capital raised Jade Biosciences to a "strong-buy" rating in a research report on Friday...

Jade Biosciences, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was founded by Benjamin T. Dake on July 27, 2018 and is headquartered in Waltham, MA.

Jade Biosciences Inc

Sprott Silver Miners & Physical Silver ETF ($SLVR)

Tradr 2x Long Innovation 100 Monthly ($MQQQ)

GraniteShares Autocallable NVDA ETF ($ANV)

Direxion Daily ASML Bull 2x ($ASMU)

The ultimate tool for the active trader. This award goes to the fund that helped traders master the market—whether by protecting against risks or jumping on the latest trends to capture quick wins.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.48	--	--	N/A
Q4 '25	-$0.48	-$0.45	6.41%	BEAT
Q3 '25	-$0.67	-$0.48	28.42%	BEAT
Q2 '25	-$0.43	-$0.86	-98.49%	MISSED
Q1 '25	--	-$12.10	--	N/A

JBIO
Jade Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest JBIO News

JBIOJade Biosciences Inc